chang recommend
upgrad outperform ill
 pt
volatil suppli chain stock continu strong
continu increasingli view lab safe
less expos polit risk big bad amazon posit
fundament dynam posit lh favor vs last year
pama headwind amidst solid execut growth uptick
much greater anticip furthermor quest specif
path redempt new manag last
sever year featur epic turnaround share
back acceler growth effect manag cost deploy
capit eras nearli decad futil today updat in-
line rate outperform pt make sure check
deep-div slide deck next page see key takeaway
pama still remain hit price sizabl windfal tax
reform allow manag smooth impact ep growth
still sacrif invest busi
clariti respect aet turn
net beneficiari increment volum industri color
price appear favor vs expect
 would impli commerci govern price
like remain stabl medium term
stark contrast remaind healthcar servic
see improv case market share gain increment
volum lh
 mix outright share gain non-pref
vendor key contract tailwind
well step outreach pl deal smaller
provid struggl post pama new realiti
 increment volum turn aid margin oper
incom growth lead shift ep growth high-
singl digit potenti low doubl digit
coupl attract dividend yield
offer tsr solidli doubl digit surprisingli low
work rel valuat also suggest multipl lab
improv time settl rang vs
recent histor
also dont forget tune webinar go thought
et
link webinar
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
upgrad quest outperform
rais pt
last page report import disclosur regard stock report
tabl content
year price compress behind us volum growth acceler
pama challeng hospit outreach acceler
contract updat best case scenario
piec togeth what right multipl
conclus upgrad outperform pt
execut summari upgrad outperform
lab bastion safeti within tough hc servic tape offer rare mix low risk doubl digit tsr
last sever year featur epic turnaround share manag acceler
growth effect manag cost deploy capit eras nearli decad futil
multi-year bull run surprisingli interrupt unfavor outcom pama uncertainti
key contract re-pric also present potenti risk headwind ep
pama still remain hit price sizeabl windfal tax reform allow manag smooth
impact ep growth still sacrif invest busi
furthermor clariti respect aet turn net beneficiari
increment volum industri color price appear favor vs expect
would impli commerci govern price like remain stabl medium
term stark contrast remaind healthcar servic complex
addit see improv case market share gain increment volum lh
mix outright share gain non-pref vendor key contract tailwind
well step outreach pl deal smaller provid struggl new realiti
increment volum turn aid margin oper incom growth lead shift ep growth
high-singl digit potenti low doubl digit
coupl attract dividend yield offer tsr solidli doubl
digit surprisingli low risk profil
work rel valuat also suggest multipl lab improv time
settl rang vs recent histor
upgrad share outperform lab broadli prefer safe
year price compress behind us
volum growth pois acceler
pama last major price cut may actual catalyz
headwind materi wors fear
could actual prove bless disguis
updat price clinic lab test issu
pama gone well lab complex
obviou reason cut spend per annum
lh challeng object
process use determin rate via acla
hospit base player still learn financi pain
struggl logic use end
ultim price approach cut stay
sell-sid model adjust realiti
said see increment headwind
manag ep standpoint thank trump tax
benefit also highlight possibl may result
long await volum shift lower cost lh
result pama price cut player outsid
like struggl increas awar
payer could incentiv shift lower cost provid
largest lab choos monet outreach
asset other look partner given disadvantag
help mix share gain
view system benefit lab gain much
need increment volum posit
think lt could take close
half independ lab market combin
opportun bn next year see
next slide detail
similar sub-seg hc lh/dgx could becom profound player oligopolist indpt lab market
right side industri shift pama
total market outsid hospit vs inpt
hospit
bp bp
could take share outsid hospit market
assum bn lab market outsid
hospit market make bn
portion includ
independ lab hospit outreach
roughli market bn
revenu
major in-network medicar
medicaid busi portion
contract also open close
insur live access marketplac
compani state focu bring
broadest array diagnost routin
esoter major growth driver
alreadi start lay seed
anticip contract open
invest psc sale forc etc
total mm tax reform save
view captur addit
share bn market time
uptick outreach pl deal
like given current market dynam
region lab also like cede
network share vbc environ
outsid hospit market
outsid hospit market
futur oligopolist indpt market w/ lh leader
lh current hold indpt market
consum incentiv go dgx/lh
outsid
outsid
current marketplac lh lot room grow runway oppti
pama challeng hospit outreach acceler
new paradigm aid increas
deal activ lab space hot last year see pick-up
dgx creativ capit effici approach a/partnership aid valu creation vendor face hard decis
updat reimburs lab test kick januari pama uncertainti drive big part
thesi lab space mani hospit laboratori like look big nation provid
lh effort gener save also provid best qualiti lab servic patient
throughout activ pursu greater level partnership lab manag arrang vs
histori slower start anticip materi uptick hospit face
second round cut acla challeng ultim decid valuat also reset lower
addit upsid contract estim roughli
mm next year attract tuck-in acquisit share repurchas dividend
histor made major compani capit deploy last year
oper incom growth improv balanc sheet util also possibl drive upsid
scenario analysi add quest earn growth
dividend share repurchas solid remain strateg tuck-in attract multipl
div paid
remain left buy-back post div
remain
avail
impli upsid ep
upsid ep
model roughli bn
dividend yield like stay histor averag
impli dividend repres roughli
mm paid
model mm share repo leav mm
remain
addit quest debt capac b/
lever gross debt ebitda
lever turn would impli
addit cash potenti
serv anoth sourc increment ep power
assum mm avail next
two year appli averag ev/rev multipl
small-to-averag size unique-test dx asset
impli modest upsid ep
would run-rat time deal would
share repo execut lead tsr acceler
ep growth hsd-ldd rang yr average
repurchas robust dividend compel return capit
assum mm revenue contribut would add ep growth respect
growth uptick due
contribut
 boost revenu growth
growth acceler consist hallmark
solid track record meet beat top bottom line expect
contract updat best case scenario
multi-year visibl thing servic
net impact contract favor
pick aet contract lost w/ price down/up lsd ep could lift
share loss aet
ep impact share loss
ep impact repric
total ep headwind aet
share gain
revenu share gain
ep impact share gain
gain access largest privat payer enough buffer
lost volum aet contract
commerci market certainti forese futur
given repric minim dgx posit respect commerci payor also posit skew
one assum stark contrast prior iter contract negoti stabl price
broad posit implic key commerci contract renew
recal contract went sole sourc exchang steep price cut share react highli
unfavor creat elev period uncertainti commerci price compress
note price gener mute manag ex pama
suggest improv volum growth play translat better profit growth
price unlik wipe gain somewhat seen prior cycl
number move part assumpt share loss aet contract share gain
contract level price degrad retain portion contract loss oon profit
in-network access mm medic enrolle aet mm
harmful/slightli accret near term increasingli posit go forward
detail agreement scarc howev key assumpt
price cut manag contract base/market-bas price
feel good potenti upsid base perform
loss oon profit contract minim
manag state small portion revenu oon lower negoti rate
fulli contempl ultim better fulli in-network
prior contract proport dgx oon profit fulli insur live within
get paid offset bit reduct oon profit
compani paid visit despit lower rate
lest forget non-pref network opportun
base rough estim unh lab spend bn give big play field compet
lab spend total
gain access unh mm plan member
open plethora opportun chang
made benefit design initi payer
outsid in-network relationship payer
non-pref market opportun
number smaller independ region
seen bar chart right base
rough estim unh total medic spend
lab spend non-pref segment repres
opportun avail
end day pay better
in-network serv
prefer provid industri shift focu
better price qualiti valu amidst pama cut
quest lh domin competitor
segment provid anoth lever increment
lab
market outsid
hospit vs
lh
piec togeth what right multipl
path dd tsr lt strateg option
dgx/lh ltm forward price-to-earnings still trade discount prior period heavi
peer group includ compani market cap bn
tsr stock price return div
attract risk/reward profil trade price-to-earnings tsr base estim
contend multipl expans rang price-to-earnings basi
upgrad quest outperform
rais pt
conclus upgrad outperform
volatil rx suppli chain stock continu strong continu increasingli view lab
safe
less expos polit risk big bad amazon posit fundament dynam
posit lh favor vs last year pama headwind amidst solid execut
growth uptick much greater anticip
furthermor quest specif path redempt new manag led return
growth strong margin disciplin bia toward strong capit return
two big overhang pama pend contract feel confid around multi-year visibl
respect price stabil addit multipl lever increment volum captur driven benefit design
chang payer acceler smaller independ lab felt pressur pama
piec put togeth make path dd tsr opinion current captur multipl today
addit long term strateg option
lab remain one healthcar servic subsector ex mco invest point recommend
group broadli lh appropri growth dividend growth
today updat in-lin rate outperform pt translat tsr
multipl expans pe basi
lever enabl hsd dd tsr acceler allow multipl expans
cmss decis guid price hit
hit
view pama hit revenu go somewher
detail scarc base base case assumpt
detail slide model bp increment top-line
growth contract chang manag price
degrad translat ep
potenti chang benefit
detail slide signific opportun
key beneficiari chang benefit design better price
qualiti valu push payer two provid
detail slide pama challeng within hospit
outreach like acceler expect
continu strateg tuck in model growth ep
contribut
event path look go ward
detail
new
quest diagnost stat million except per share data fy end septemb volum organ gp growth revenu margin ep share net incom price-to-earnings premium/discount isi healthcar technolog distribut juli
valuat price target base dcf methodolog contempl wacc termin ebitda multipl
equat perpetu growth rate pt translat ebitda vs average
downsid risk challeng associ integr small outreach lab deal could depress return invest capit
prove distract recent vertic integr hc servic organ lead increas price pressur given heighten
focu unit cost potenti pama relat price cut bleed commerci price ultim lead neg
upsid risk pama repriev lead ep upward revis remov key growth overhang allow resumpt
pe expans open contract favor econom allow lh reap benefit expens small
player pressur small lab lead materi up-tick activ highli attract price allow notabl b/
laboratori corp america hold
articl articl
time dissemin juli et
analyst ross muken elizabeth anderson suzi yoon primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view
